Skip to main content
Sign In
 

Antonio Jimeno, MD, PhD

Associate Professor, Division of Medical Oncology


 Jimeno Photo

Education MD, PhD

University of Valladolid, Spain
University Complutense, Madrid, Spain

Dr. Jimeno joined the UCD Faculty in April 2008 as the Director of the Developmental Therapeutics/Pharmacodynamic Laboratory and as a member of the Drug Development Program. He trained in Internal Medicine and Medical Oncology at the University Hospital 12 de Octubre in Madrid, Spain. After completing his training as a clinical researcher in the context of a Drug Development Clinical Fellowship at Johns Hopkins from 2003 to 2006, Dr. Jimeno joined the Faculty at Johns Hopkins as Instructor of Oncology in July 2006.

 

Research
Dr. Jimeno has developed an interest in integrating preclinical research, drug development, and clinical research. He has made a special emphasis in 1) developing better preclinical models, 2) determining predictors of response, and 3) devising ways to integrate that knowledge into clinical trials to individualize anti-cancer therapy. His concomitant work in the laboratory and the clinic has materialized in the form of novel inventions (drugs and biomarkers) that are currently the subject of prospective clinical testing. His clinical interest is Head and Neck and Upper Gastrointestinal cancer. He has been recognized for his research efforts with an ASCO Young Investigator Award in 2005, and two ASCO Merit Awards in 2004 and 2006. 

Publications

Keysar SB, Astling DP, Anderson RT, Vogler BW, Paylor JJ, Morton JJ, Paylor JJ, Takimoto SM, Kako SL, Glogowska MJ, Sehrt DB, Le PN, Macfadden SM, Pittman MA, Helber RA, Peterson S, Hausman D, Said S, Robinson WA, Leem TH, Goddard JA, Arcaroli J, Messersmith WA, Hirsch F, Varella-Garcia M, Raben D, Song JI, Wang XJ, Tan AC, Jimeno A. A direct patient tumor model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in the presence of human papillomavirus, and Pi3kca or Notch1 mutations. Mol Oncol 2013.

Keysar SB, Le P, Anderson RT, Astling DP, Vogler BW, Bowles DW, Morton JJ, Paylor JJ, Fernandez P, Glogowska MJ, Thornburn J, Takimoto S, Sehrt D, Bowles DW, Macfadden SM, Pittman MA, Helber RA, Said S, Raben DR, CampbellV, Kutock J, McGovern K, Thornburn A, Song JI, Tan AC, Wang XJ, Jimeno A. The hedgehog pathway influences epidermal growth factor receptor (EGFR) signaling dependence and acquisition of resistance to anti-EGFR therapy in head and neck squamous cell cancer. Cancer Res 2013.

Hong DS, Bowles D, Falchook GS, Messersmith WA, Goldy G, O’Bryant C, Herbst RS, Eckhardt SG, Vo A, Peterson S, Hausman DF, Kurzrock R, Jimeno A. A Phase 1 study of PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase. Clin Cancer Res 2012.

Jimeno A, Weiss GJ, Miller WH, Gettinger S, Eigl B, Chang ALS, Dunbar J, Devens S, Faia K, Skliris G, Kutok J, Lewis KD, Tibes R, Sharfman WH, Ross RW, Rudin CM. Phase 1 Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors. Clinical Cancer Res 2013.

 

Funding

  • NIH R01CA149456
  • NIH R21DE019712
  • Department of Defense CA093422
  • NIH R21CA156114
 
University of Colorado Denver

© The Regents of the University of Colorado, a body corporate. All rights reserved.

All trademarks are registered property of the University. Used by permission only.